Midatech Group and MonoSol Rx Enter Collaboration Agreement to Unite Nanoparticle and Thin Film Drug Delivery Technologies

Potential to Develop New Oral Drug Candidates with Superior Efficacy, Safety, Convenience, and Commercial Potential

10-Nov-2008 - United Kingdom

Midatech Group and MonoSol Rx announced a partnership to develop new drug formulations combining biocompatible nanoparticles and PharmFilm delivery technologies.

Under terms of the agreement, Midatech Ltd and MonoSol Rx will jointly research, develop and commercialize new drug candidates designed to deliver therapeutic nanoparticles in thin film. Research and development will occur at Midatech Biogune S.L., in Bilbao, Spain with clinical development at a new facility in Basel, Switzerland. MonoSol Rx’s facility in Portage, Indiana is critical in these joint activities. Further terms were not disclosed.

Other news from the department business & finance

These products might interest you

Eclipse

Eclipse by Wyatt Technology

FFF-MALS system for separation and characterization of macromolecules and nanoparticles

The latest and most innovative FFF system designed for highest usability, robustness and data quality

DynaPro Plate Reader III

DynaPro Plate Reader III by Wyatt Technology

Screening of biopharmaceuticals and proteins with high-throughput dynamic light scattering (DLS)

Efficiently characterize your sample quality and stability from lead discovery to quality control

particle analyzers
Loading...

More news from our other portals

All FT-IR spectrometer manufacturers at a glance